-+ 0.00%
-+ 0.00%
-+ 0.00%

These Analysts Revise Their Forecasts On Haemonetics After Q3 Earnings

Benzinga·02/06/2026 17:28:04
Listen to the news

Haemonetics Corporation (NYSE:HAE) reported upbeat earnings for its third quarter on Thursday.

The company posted quarterly earnings of $1.31 per share which beat the analyst consensus estimate of $1.25 per share. The company reported quarterly sales of $338.967 million which beat the analyst consensus estimate of $331.616 million.

Haemonetics raised its FY2026 adjusted EPS guidance from $4.80-$5.00 to $4.90-$5.00.

Haemonetics shares fell 6% to trade at $61.13 on Friday.

These analysts made changes to their price targets on Haemonetics following earnings announcement.

  • Barrington Research analyst Michael Petusky maintained Haemonetics with an Outperform rating and raised the price target from $93 to $94.
  • Mizuho analyst Anthony Petrone maintained the stock with an Outperform rating and lowered the price target from $90 to $80.

Considering buying HAE stock? Here’s what analysts think:

Photo via Shutterstock